Are Ethnicity and Duration of Natalizumab Exposure Risk Factors for JCV Infection?December 1, 2012Multiple Sclerosis
Physicians, Patients Differ in Weighing Benefits Versus Side Effects of MS TherapiesNovember 1, 2012Multiple Sclerosis
John DeLuca, PhD, Discusses the Assessment and Rehabilitation of Cognitive Impairment in Multiple SclerosisOctober 1, 2012Multiple Sclerosis
Anthony Reder, MD, Discusses a 21-Year Follow-Up Study of Patients Who Have Multiple SclerosisSeptember 1, 2012Multiple Sclerosis
Should Patients Continue Natalizumab Treatment After a Positive JCV Test?August 1, 2012Multiple Sclerosis
